|
|
8th Industry/Academia Translational Oncology Symposium
Thursday March 22, 2012 | 8AM - 6PM
Join distinguished investigators and clinicians from academia and top industry representatives in the discussion on the latest breakthroughs and applications in translational oncology. The talks feature important translational oncology discoveries and focus on industry/academia collaboration to overcome the translational gap in cancer drug development. An interactive panel session comprised of industry and academia panelists and a networking reception encourage further dialogue amongst all participants and speakers about collaborative translational oncology projects, driving innovation to better serve patients.
Symposium Organizer:
Thomas Kipps, MD, PhD
Director
UCSD Moores Cancer Center
Symposium Organizer:
Ida Deichaite, PhD
Director, Industry Relations
UCSD Moores Cancer Center
|
Symposium Chair:
David Cheresh, PhD
Associate Director for Translational Research
Professor of Pathology
UCSD Moores Cancer Center
Symposium Co-Chair:
Catriona Jamieson, MD, PhD
Director, Stem Cell Research Program
Associate Professor of Medicine
UCSD Moores Cancer Center
|
Symposium Agenda
8:15AM
|
Registration and Continental Breakfast
|
8:45AM
|
Welcome and Overview
|
- David Brenner, MD, UC San Diego School of Medicine
- Thomas Kipps, MD, PhD, Moores Cancer Center
|
9:00AM
|
- Armed with Genomics, Is the Target in Sight for Myelodysplastic Syndromes?
Azra Raza, MD, MDS Center, Columbia University Medical Center
|
9:20AM
|
Session: Cilengitide, a New Therapeutic for Brain Cancer, from Bench to Bedside and Back
|
- Cilengitide, from Discovery to Clinical Development and Back
David Cheresh, PhD, Moores Cancer Center
- Targeting for Glioblastoma Patients with Cilengitide: Promises and Challenges
David Reardon, MD, Center for Neuro-Oncology, Dana-Farber Cancer Institute
|
10:15AM
|
Break
|
10:30AM
|
Session: Successful Industry Academia Collaboration
|
- Malignant Progenitor Re-Programming
Catriona Jamieson, MD, PhD, Moores Cancer Center
|
11:30AM
|
Keynote Presentation
|
- Stem Cells and Cancer
Irving Weissman, MD, Stanford School of Medicine
|
12:00PM
|
Lunch
|
1:15PM
|
Session: First in Class Cancer Drug Pipeline
|
- PAK Inhibitors for Cancer – Trailblazing a Path to the Clinic
David Campbell, PhD, Afraxis
- Targeting Pim Kinases in Hematological Malignancies
Erika Keeton, PhD, AstraZeneca Pharmaceuticals
- The Mouse that ROR'ed – Targeting Onco-Embryonic Antigens
Thomas Kipps, MD, PhD, Moores Cancer Center
- From Phenotypic Screen to a Druggable Node in the Wnt Pathway
Martin Seidel, PhD, Genomics Institute of the Novartis Research Foundation
|
2:40PM
|
- Understanding Rejection (How and Why) through the Melanoma Model
Francesco Marincola, MD, National Institutes of Health
|
3:00PM
|
- The Challenge of a Biosimilar Development
Udo Müller, MD, PhD, Teva Pharmaceuticals
|
3:25PM
|
Break
|
3:40PM
|
- The New Center for Innovative Therapies: A University-Industry Partnership to Discover and Develop New Treatments and Cures
Marye Anne Fox, PhD, Chancellor, University of California San Diego
Thomas Kipps, MD, PhD, Moores Cancer Center
|
4:00PM
|
Panel Discussion: Discovery to Therapies…It’s Changing and Quickly
|
- Moderator: Duane Roth, CONNECT
- Robert Abraham, PhD, Pfizer
- Sandra Brown, PhD, UC San Diego School of Medicine
- Dennis Carson, MD, PhD, Moores Cancer Center
- David Kabakoff, PhD, Sofinnova Ventures
- Jonathan Thomas, PhD, JD, CIRM
- Carl Weissman, Accelerator
|
5:00PM
|
Symposium Reception
|
We Thank Our Supporters:
|
